Table 3 Resistance rates (%) of major gram-negative bacteria of PBM patients in China, 2016–2018
Antimicrobial agent | Eco A/B (%) | Kpn A/B (%) | Aba A/B (%) | Pae A/B (%) |
|---|---|---|---|---|
Ampicillin | 105/125 (84.0) | 25/26 (96.2) | 14/18 (77.8) | 12/13 (92.3) |
Piperacillin | 56/68 (82.4) | 11/14 (78.6) | 3/5 (60.0) | 5/13 (38.5) |
Cefazolin | 52/104 (50.0) | 18/23 (78.3) | – | – |
Cefuroxime | 11/21 (52.4) | 4/8 (50.0) | – | – |
Cefoxitin | 0/30 (0) | 5/8 (62.5) | – | – |
Ceftriaxone | 44/89 (49.4) | 10/15 (66.7) | 8/15 (53.3) | – |
Cefotaxime | 30/61 (49.2) | 14/20 (70.0) | 5/8 (62.5) | – |
Ceftazidime | 38/140 (26.4) | 20/32 (62.5) | 8/21 (38.1) | 5/16 (31.2) |
Cefepime | 45/140 (32.1) | 17/32 (53.1) | 7/21 (33.3) | 3/17 (17.6) |
Amoxicillin/clavulanic acid | – | – | 8/13 (61.5) | – |
Ampicillin/Sulbactam | 58/102 (56.9) | 20/26 (76.9) | 5/15 (33.3) | 7/7 (100) |
Piperacillin/tazobactam | 3/122 (2.5) | 20/30 (66.7) | 5/12 (41.7) | 4/10 (40.0) |
Cefoperazone/sulbactam | 1/17 (5.9) | – | – | – |
Tobramycin | 23/56 (41.1) | 2/8 (25.0) | 1/10 (10.0) | ¼ (25.0) |
Gentamicin | 49/127 (38.6) | 13/30 (43.3) | 5/19 (41.7) | 2/13 (15.4) |
Amikacin | 0/142 (0) | 11/31 (35.5) | 2/16 (12.5) | 1/16 (6.2) |
Ciprofloxacin | 73/131 (55.7) | 12/29 (41.4) | 5/20 (25.0) | 1/13 (7.7) |
Levofloxacin | 74/138 (53.6) | 12/32 (37.5) | 5/21 (23.8) | 3/16 (18.8) |
Aztreonam | 43/124 (34.7) | 17/26 (65.4) | – | 2/4 (50.0) |
Tetracycline | 60/76 (78.9) | 9/30 (30.0) | 5/9 (55.6) | – |
Co-trimoxazole | 97/141 (68.8) | 5/34 (14.7) | 13/22 (59.1) | – |
Meropenem | 6/88 (6.8) | 16/25 (64.0) | 6/11 (54.5) | 2/13 (15.4) |
Ertapenem | 0/79 (0) | 1/12 (8.3) | – | – |
Imipenem | 4/140 (2.9) | 5/22 (22.7) | 6/19 (31.6) | 6/16 (37.5) |